Filament Health Corp (NEO:FH, OTCQB:FLHLF) announced that it has expanded its intellectual property portfolio with the acceptance of 12 patents for processes relating to the development of botanical psychedelic drugs by IP Australia.
The clinical-stage natural psychedelic drug developer said it has also been issued another five patents by the Canadian Intellectual Property Office and three patents by the United States Patent and Trademark Office for methods of extraction, purification, standardization, and delivery of naturally-derived psychedelic drug candidates.
It holds a total of 46 accepted patents from Canada, the United States, Australia and Mexico.
"Our intellectual property represents a unique derisking of the psychedelic business model," Filament Health director of intellectual property Taran Grey said in a statement.
"Our patents do not protect just one of thousands of possible synthetic polymorphs, but rather the most efficient means to produce naturally-derived, complex APIs with the potential to significantly improve patient outcomes. We will continue to grow our operations globally with confidence in the security of our innovations."
Filament Health CEO Benjamin Lightburn expressed his pleasure in seeing the company’s technology continue to be recognized internationally.
"As the premier global supplier of cGMP botanical psilocybin, the protection of Filament's drug candidates and intellectual property is critical for the distribution of our drug products to support clinicians, patients and the continuation of psychedelic research and development around the world," Lightburn said.